Year: 2021

VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific article entitled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma”, has been published in Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease), a leading international journal focused on biochemistry and molecular genetics of disease processes and models of human disease in the area of aging, cancer, metabolic-, neurological-, and immunological-based diseases.  The peer-reviewed article highlights research evaluating the use of cannabinol, or CBN, as a potential treatment...

TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) — Probe Metals Inc. (TSX-V: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to announce that it has raised $7.0 million from the exercise of 5,376,249 share purchase warrants with a strike price of $1.30 (the “Warrants”). The Warrants were originally issued as part of the private placement completed in December 2019. As of today, the Company has approximately $31.4 million in cash and investments. David Palmer, President and CEO of Probe, states, “The exercise of warrants has not only strengthened our balance sheet but also demonstrates the strong support we have from our existing shareholders. 2021 has been an incredibly successful year for the Company, crossing the 4 million ounce threshold for Val-d’Or and issuing a PEA that shows profitable mining operations of well over 200,000...

JSC ‘Siguldas ciltslietu un mākslīgās apsēklošanas stacija’ (Nasdaq Riga: SCM1R) informs that in 2022 the dissemination of its audited annual report, interim reports and financial information is planned on dates as follows:Date   Event21th March 2022 for the year 202126th May 2022 for the first 3 month period of 202225th August 2022 for the first 6 month period of 202224th November 2022 for the 9 month period of 2022Valda Mālniece Financial and accounting department manager, member of the management board E-mail: valda.malniece@sigmas.lv

Radisson Blu Hotel, Mount Erciyes Hotel ViewRadisson Blu Hotel, Mount Erciyes Hotel ViewRadisson Blu Hotel, Mount Erciyes Restaurant FireplaceRadisson Blu Hotel, Mount Erciyes Restaurant FireplaceRadisson Blu Hotel, Mount Erciyes Guest RoomRadisson Blu Hotel, Mount Erciyes Guest RoomRadisson Blu Hotel, Mount Erciyes Room ViewRadisson Blu Hotel, Mount Erciyes Room ViewRadisson Blu Hotel, Mount Erciyes Guest Room Living AreaRadisson Blu Hotel, Mount Erciyes Guest Room Living AreaRadisson Blu Hotel, Mount Erciyes RestaurantRadisson Blu Hotel, Mount Erciyes RestaurantRadisson Blu Hotel Mount Erciyes lobby areaRadisson Blu Hotel Mount Erciyes lobby areaRadisson Blu Hotel Mount Erciyes lobby detailsRadisson Blu...

EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia Editas Medicine will initiate a Phase 1/2 clinical trial in 2022 CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling the Company to initiate a Phase 1/2 clinical study of EDIT-301 in TDT patients. EDIT-301 is an experimental gene editing medicine designed to be a transformative, one-time treatment for people living with severe sickle cell disease (SCD) or TDT. EDIT-301 uses CRISPR/Cas12a gene editing technology to precisely make a DNA change that restores production...

SOMERVILLE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the promotion of Joseph Vittiglio, JD, to Chief Business and Legal Officer. Mr. Vittiglio has more than 25 years of experience leading strategic transactions within the life sciences industry. “Joe’s breadth of experience building successful biotech companies and catalyzing strategic partnerships is invaluable to Finch as we continue to advance our platform and expand our pipeline of microbiome product candidates,” said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. “As a platform company, we believe that...

CALGARY, Alberta, Dec. 20, 2021 (GLOBE NEWSWIRE) — Eguana Technologies (TSX.V: EGT) (OTCQB: EGTYF) today announced it has received an opening order of 500 units representing 2.5MW from partner PowerCenter+, a subsidiary of Eguana manufacturing partner Omega EMS. The initial order, valued at approximately $6M, is related to the previously released manufacturing and licensing agreements between the parties to launch a premium line of home energy storage systems (ESS) based on Eguana’s patented energy storage platform. “We are extremely excited to see all of the hard work bear fruit as our first ESS offering enters the market. This is our entrée to bring effective, efficient and very reliable energy storage to homeowners. 2022 will be an explosive year as we gain a strong foothold and grow market share,” stated Chris Alessio, CEO...